These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31608328)

  • 21. Spatial and temporal proteome dynamics of glioma cells during oncolytic adenovirus Delta-24-RGD infection.
    González-Morales A; Zabaleta A; Guruceaga E; Alonso MM; García-Moure M; Fernández-Irigoyen J; Santamaría E
    Oncotarget; 2018 Jul; 9(57):31045-31065. PubMed ID: 30123426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic concentrations of anti-epileptic drugs do not inhibit the activity of the oncolytic adenovirus Delta24-RGD in malignant glioma.
    de Jonge J; Berghauser Pont LM; Idema S; Kloezeman JJ; Noske D; Dirven CM; Lamfers ML
    J Gene Med; 2013; 15(3-4):134-41. PubMed ID: 23606319
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of T-cell-mediated anti-tumour immunity via the ectopically expressed glucocorticoid-induced tumour necrosis factor receptor-related receptor ligand (GITRL) on tumours.
    Piao J; Kamimura Y; Iwai H; Cao Y; Kikuchi K; Hashiguchi M; Masunaga T; Jiang H; Tamura K; Sakaguchi S; Azuma M
    Immunology; 2009 Aug; 127(4):489-99. PubMed ID: 19604302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8
    Kleijn A; van den Bossche W; Haefner ES; Belcaid Z; Burghoorn-Maas C; Kloezeman JJ; Pas SD; Leenstra S; Debets R; de Vrij J; Dirven CMF; Lamfers MLM
    Mol Ther Oncolytics; 2017 Jun; 5():11-19. PubMed ID: 28480325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-modified oncolytic adenovirus armed with a recombinant interferon-like gene enhanced abscopal effects against malignant glioma.
    Jiang S; Chai HH; Fang XL; Xu HS; Li TW; Tang QS; Gu JF; Zhang KJ; Liu XY; Shi ZF; Cao XP; Wu ZY; Zhou LF
    Neurooncol Adv; 2023; 5(1):vdad117. PubMed ID: 37841695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
    Lee YS; Kim JH; Choi KJ; Choi IK; Kim H; Cho S; Cho BC; Yun CO
    Clin Cancer Res; 2006 Oct; 12(19):5859-68. PubMed ID: 17020994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.
    Kostova Y; Mantwill K; Holm PS; Anton M
    Cancer Gene Ther; 2015 Jan; 22(1):30-43. PubMed ID: 25501992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.
    Ulasov IV; Zhu ZB; Tyler MA; Han Y; Rivera AA; Khramtsov A; Curiel DT; Lesniak MS
    Hum Gene Ther; 2007 Jul; 18(7):589-602. PubMed ID: 17630837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas.
    Jiang H; Gomez-Manzano C; Lang FF; Alemany R; Fueyo J
    Curr Gene Ther; 2009 Oct; 9(5):422-7. PubMed ID: 19860656
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy.
    Lamfers ML; Grill J; Dirven CM; Van Beusechem VW; Geoerger B; Van Den Berg J; Alemany R; Fueyo J; Curiel DT; Vassal G; Pinedo HM; Vandertop WP; Gerritsen WR
    Cancer Res; 2002 Oct; 62(20):5736-42. PubMed ID: 12384532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma.
    Sonabend AM; Ulasov IV; Tyler MA; Rivera AA; Mathis JM; Lesniak MS
    Stem Cells; 2008 Mar; 26(3):831-41. PubMed ID: 18192232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential effects of combined Ad5- delta 24RGD and radiation therapy in in vitro versus in vivo models of malignant glioma.
    Lamfers ML; Idema S; Bosscher L; Heukelom S; Moeniralm S; van der Meulen-Muileman IH; Overmeer RM; van der Valk P; van Beusechem VW; Gerritsen WR; Vandertop WP; Dirven CM
    Clin Cancer Res; 2007 Dec; 13(24):7451-8. PubMed ID: 18094429
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.
    Kleijn A; Kloezeman J; Treffers-Westerlaken E; Fulci G; Leenstra S; Dirven C; Debets R; Lamfers M
    Oncoimmunology; 2014 Oct; 3(9):e955697. PubMed ID: 25941622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut microbiota composition is associated with the efficacy of Delta-24-RGDOX in malignant gliomas.
    Meléndez-Vázquez NM; Nguyen TT; Fan X; López-Rivas AR; Fueyo J; Gomez-Manzano C; Godoy-Vitorino F
    Mol Ther Oncol; 2024 Mar; 32(1):200787. PubMed ID: 38596290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas.
    Yong RL; Shinojima N; Fueyo J; Gumin J; Vecil GG; Marini FC; Bogler O; Andreeff M; Lang FF
    Cancer Res; 2009 Dec; 69(23):8932-40. PubMed ID: 19920199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
    Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
    Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection.
    Grekova SP; Raykov Z; Zawatzky R; Rommelaere J; Koch U
    Cancer Gene Ther; 2012 Jul; 19(7):468-75. PubMed ID: 22539062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality.
    Richards DM; Marschall V; Billian-Frey K; Heinonen K; Merz C; Redondo Müller M; Sefrin JP; Schröder M; Sykora J; Fricke H; Hill O; Gieffers C; Thiemann M
    J Immunother Cancer; 2019 Jul; 7(1):191. PubMed ID: 31324216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.
    Edukulla R; Woller N; Mundt B; Knocke S; Gürlevik E; Saborowski M; Malek N; Manns MP; Wirth T; Kühnel F; Kubicka S
    Cancer Res; 2009 Feb; 69(4):1448-58. PubMed ID: 19190348
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.
    Barnard Z; Wakimoto H; Zaupa C; Patel AP; Klehm J; Martuza RL; Rabkin SD; Curry WT
    Neurosurgery; 2012 Sep; 71(3):741-8; discussion 748. PubMed ID: 22653387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.